Archives of gynecology and obstetrics · 2026
One-year outcome after laser treatment of vulvar lichen sclerosus: a prospective observational trial.
СтатьяНаблюдательное исследованиеРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gamper Marianne, Zivanovic Irena, Bischofberger Helena, Viereck Volker
Аннотация
PURPOSE: To assess the 12-month efficacy of a novel non-ablative dual Nd:YAG/Er:YAG laser therapy for vulvar lichen sclerosus (LS) and to evaluate the impact of crossover laser treatment following initial topical corticosteroid therapy.
METHODS: This study presents the 1-year data of a prospective observational trial. Between baseline and 6 months, women with vulvar LS were randomized to receive either dual Nd:YAG/Er:YAG laser therapy or topical clobetasol propionate. Between 6 and 12 months, optional steroid or laser therapies were offered.
RESULTS: In the laser group, 34 of 44 patients (77%) required no additional treatment between 6 and 12 months, indicating sustained treatment effects. The total LS score improved significantly during this period (mean change -0.35 ± 0.60; 95% CI -0.56 to -0.14; p = 0.004), while other parameters showed non-significant improvements. In the corticosteroid group, 20 of 22 patients (91%) opted for a crossover to laser therapy. Following three laser sessions, the total LS score improved markedly (mean change -1.50 ± 0.83; 95% CI -1.89 to -1.11; p < 0.001), primarily driven by a reduction in atrophy (p < 0.001). Patient-reported improvement (PGI-I) increased from 45 to 77% (p = 0.008). At the 12-month follow-up, outcomes were comparable between the two study groups.
CONCLUSION: Non-ablative dual Nd:YAG/Er:YAG laser therapy resulted in significant and sustained clinical improvement in vulvar LS over 12 months. Crossover to laser therapy after initial corticosteroid treatment further enhanced both objective and subjective outcomes.
CLINICAL TRIAL IDENTIFICATION NUMBER: NCT03926299; date of registration: 24 April 2019.
METHODS: This study presents the 1-year data of a prospective observational trial. Between baseline and 6 months, women with vulvar LS were randomized to receive either dual Nd:YAG/Er:YAG laser therapy or topical clobetasol propionate. Between 6 and 12 months, optional steroid or laser therapies were offered.
RESULTS: In the laser group, 34 of 44 patients (77%) required no additional treatment between 6 and 12 months, indicating sustained treatment effects. The total LS score improved significantly during this period (mean change -0.35 ± 0.60; 95% CI -0.56 to -0.14; p = 0.004), while other parameters showed non-significant improvements. In the corticosteroid group, 20 of 22 patients (91%) opted for a crossover to laser therapy. Following three laser sessions, the total LS score improved markedly (mean change -1.50 ± 0.83; 95% CI -1.89 to -1.11; p < 0.001), primarily driven by a reduction in atrophy (p < 0.001). Patient-reported improvement (PGI-I) increased from 45 to 77% (p = 0.008). At the 12-month follow-up, outcomes were comparable between the two study groups.
CONCLUSION: Non-ablative dual Nd:YAG/Er:YAG laser therapy resulted in significant and sustained clinical improvement in vulvar LS over 12 months. Crossover to laser therapy after initial corticosteroid treatment further enhanced both objective and subjective outcomes.
CLINICAL TRIAL IDENTIFICATION NUMBER: NCT03926299; date of registration: 24 April 2019.